Counterfeit cancer drugs: NAFDAC raises alarm over fake Avastin, Tecentriq

Nigeria's pharmaceutical regulatory authority has sounded an urgent warning about the proliferation of counterfeit versions of two critical cancer medications—Avastin and Tecentriq—circulating throughout the country's healthcare system. This development represents far more than a public health emergency; it signals systemic weaknesses in Nigeria's drug supply chain that pose significant financial and reputational risks for European pharmaceutical companies and investors operating across West Africa. Avastin (bevacizumab) and Tecentriq (atezolizumab) are sophisticated biopharmaceutical products manufactured by Roche, one of Europe's largest pharmaceutical corporations. These drugs target various cancers and command premium prices reflecting their development costs and efficacy. The emergence of fake versions in Nigeria's market undermines legitimate pharmaceutical distribution networks and erodes confidence in branded medications across the entire West African region. The scale of Nigeria's counterfeit drug problem extends beyond these two products. Industry estimates suggest that between 10-20% of medications circulating in sub-Saharan African markets lack authenticity, with cancer drugs particularly vulnerable due to high profit margins and limited traceability mechanisms. For European investors in pharmaceutical distribution, manufacturing, or diagnostic services, this creates both operational challenges and market opportunities. From a market perspective, Nigeria represents Africa's largest pharmaceutical market with an estimated value exceeding $4 billion annually. However, weak